Skip to main content

Studienbüro

Wir tragen dafür Sorge, dass die Qualität unserer medizinischen Leistungen auf dem neuesten Stand und auf hohem Niveau bleibt und ständig verbessert wird. Die Teilnahme an wissenschaftlichen Studien gewährleistet, dass aktuellstes Fachwissen unmittelbar in Ihre Behandlung einfließen kann.

Klinische Studien haben dazu beigetragen, dass es heute erfolgreiche Behandlungsmethoden für Tumorerkrankungen gibt, die früher unheilbar waren.

Wer als Patient an einer Studie teilnimmt, hilft aktiv mit, dass auch künftig Fortschritte in der Behandlung von Krebserkrankungen erzielt werden können.

studienbüro pioh

frechen
Kölner Str. 9
50226 Frechen

Tel 02234 - 999 59 17, 27
Fax 02234 - 99959-26
E-Mail  Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

studienbüro pioh

köln zentrum
Richard-Wagner-Straße 13–17
Ring Colonnaden
50674 Köln
Tel 0221 - 922 868 20, 21
Fax 0221 - 922 868 19
E-Mail  Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.
Karin Lanzerath

Karin Lanzerath

Studienkoordinatorin
Schaps-Lea

Lea Schaps

Studienkoordinatorin
Kongressbeiträge / Publikationen

2023

Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE, M. Reiser, J. Uhlig, L. Jacobasch, L. Mueller, A. Schuch, L. Serrer, R. de Buhr, H.U. Siebenbach, T. Göhler, J.K. Schröder, D. Semsek, A. Koehler, P. Stübs, K.M. Potthoff, N.W. Marschner, Annals of Oncology, Volume 34, S445

 Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany, W.E.E. Eberhardt, B. Passlick, M. Stuschke, A. Groeschel, P. Christopoulos, M. Reck, P. Ludwig, A. Hipper, M. Chiabudini, L. Spring, M. Jänicke, A. Andres-Pons, D.C. Christoph, C. Bernhardt, M. Reiser, M. Sebastian, F. Griesinger, M. Thomas, AIO-TRK-0315 Eberhardt, W.E.E. et al.Annals of Oncology, Volume 33, S988

 Multiple myeloma: Antiresorptive therapy in patients with osteolytic lesions and impaired renal function- data from MYRIAM registry, Eyck von der Heyde, Marcel Reiser, Arnd Nusch, Tobias Dechow, Lutz Jacobasch, Matthias Zingerle, Christof Schweizer, Tanja Medinger, Martina Jänicke, Karin Potthoff, Monika Engelhardt, Hermann Einsele, Wolfgang Knauf, AS-DGHO-2023-00036, 13.-16. October 2023

First glance on outcome in routine care of patients with multiple myeloma in Germany- results from MYRIAM registry, Marcel Reiser, Eyck von der Heyde, Arnd Nusch, Tobias Dechow, Dieter Bürkle, Matthias Groschek, Philipp Kiewe, Timon Hansen, Christian Langer, Tanja Medinger, Martina Jänicke, Karin Potthoff, Monika Engelhardt, Hermann Einsele, Wolfgang Knauf, AS-DGHO-2023-00036, 13.-16. October 2023

Real-world outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: results from the German multicentre REALITY study; Anke Gerhardt, Steffen Dörfel, Holger Schulz, Rudolf Schlag, Lukas Vornholz, Sonja Nejad-Asgari5, Manfred Welslau, Target journal European Journal of Haematology, Key timelines, June 2023, target submission date: September 2023

Waldenstrom`s Macroglobulinemia: Routine Care in Germany 2020-2021, Weide R., Feiten S., Kojouharoff G., Otremba B., Linde H., Lorentz C., Hensel M., Schnell R., Schmidt B., Lipke J., Knoblich J., Verpoort K., Köhler A., Mohm J., Müller L., Dörfel S., Schmalfeld M., Vehling-Kaiser U., Rothe A., Steinmetz H.-T., Karcher A., Ehscheidt P., Chemnitz J.M., Lutz C., Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

CML-Registry (CML VI): Achievement of ELN-milestones is predictive for DMR in real-world setting, Kohlbrenner K., GaluschekN., Fabarius A., Reiser M., Fenchel K., Eßeling E., Göhler T., Geer T., Depenbusch R., Azeh I.T., Engel E., Hansen R., Lindemann H.-W., Jehner P., Abu-Samra M., Ritter M., Gattermann N., Pelz H., Fuxius S., Oswald B., Baerlocher G.M., Brümmendorf T.H., Heim D., le Countre P., Burchert A., Niederwieser D., Tesch H. , Hofmann W.-K., Hochhaus A., Hehlmann R., Saußele S., Deutsche CML-Studiengruppe, Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

Real-World Data on HER2-testing and treatment of patients with HER2-positive metastatic colorectal cancer – Data from the registry platform AZURITE, Bürkle D., Zahn M.-O., Sauer A., Michl M., Kullmann F., Schnell R., Hof A., Wetzel N., Boneva B., Jänicke M., Graf N., Neumann J.H., Strintzing S., Potthoff K., AZURITE registry platform, Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

Overall safety and effectiveness of the IVIG Privigen in immunodeficiencies before and after the implementation of an immunoaffinity chromatography isoagglutinin reduction step in the manufacturing process- Results from an observational study, Otremba B., Reiser M., Weide R., Pfründer D., Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

 

Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices, Franke G.-N., Löwe G., Reiser M., Linde H., Josting A., Platzbecker U.,von der Heyde E. , Weide R. , Tesch H. , Nusch A., Dengler J. , Jentsch-Ullrich K., Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

Genetic tumor profile of patients with or without clinical benefit from PD-(L)1 antibody treatment in various cancer entities- Biobank research project of the INFINITY registry, Hillebrand L.E., Vannier C., Matter M. , Läubli H., Jermann P.M., Sellmann L., Schröder J., Decker T., Schuler M., Zaiss M, Reiser M, Neise M, Grebhardt S, Wright P.R., Woerner S.M., Kasenda B. , Potthoff K., Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

Multiple myeloma: antiresorptive therapy in patients with osteolytic lesions and impaired renal function – data from the MYRIAM registry, von der Heyde E., Reiser M., Nusch A., Dechow T., Jacobasch L., Zingerle M., Schweizer C., Medinger T. , Jänicke M., Potthoff K. , Engelhardt M., Einsele H., Knauf W., MYRIAM Registry Group, Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

First glance on outcome in routine care of patients with multiple myeloma in Germany- results from the MYRIAM registry, Reiser M., von der Heyde E., Dechow T., Bürkle D., Groschek M., Kiewe P., Hansen T., Langer C., Medinger T., Jänicke M., Potthoff K., Kiewe P., Hansen T., Engelhardt M., Einsele H., Knauf W., MYRIAM Registry Group, Oncology Research Treatment, Band 46, Supplement 5, DGHO 13.-16. Oktober 2023

First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study, Tobias Dechow, Jorge Riera-Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Ursula Oppermann, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke, Dagmar Taeuscher, Manfred Welslau, Karin Potthoff, 09 February 2023, https://doi.org/10.1002/ijc.34467

 

Spotlight on the real-world treatment of CML patients in Germany: A Retrospective survey in private Oncology Practices Franke, Georg-Nikolaus; Loewe, Gunnar; Reiser, Marcel; Linde, Hartmut; Josting, Andreas; von der Heyde, Eyck; Weide, Rudolf; Tesch, Hans; Nusch, Arndt; Dengler, Jolanta; Jentsch-Ullrich, Kathleen. HemaSphere 7():p e4962270, August 2023. | DOI: 10.1097/01.HS9.0000969620.49622.70

Awareness and use of psychosocial care among cancer patients and their relatives—a comparison of people with and without a migration background in Germany. Susanne Singer, Nicola Riccetti, Isabelle Hempler, Marius Fried, Jorge Riera Knorrenschild, Louma Kalie, Martin Merbach, Marcel Reiser, Franz Mosthaf, Vitali Heidt, Kerstin Hermes Moll. J Cancer Res Clin Oncol 149, 1733–1745 (2023)

NEPTUN - First-Line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study. Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Oppermann U, Chiabudini M, Fischer von Weikersthal L, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K. Int J Cancer. 2023 Jul 1;153(1):141-152. doi: 10.1002/ijc.34467

 

2022

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. P Langerbeins, C Zhang, S Robrecht, P Cramer, M Furstenau, O Al-Sawaf, J von Tresckow, A-M Fink, K-A Kreuzer, U Vehling-Kaiser, E Tausch, L Mueller, MJ Eckart, R Schlag, W Freier, T Gaska, C Balser, M Reiser, M Stauch, C-M Wendtner, K Fischer, S Stilgenbauer, B Eichhorst, M Hallek. Blood, 2022, Volume 139, Number 2, 177-187

Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. S Luecke, C Fottner , H Lahner , H Jann, D Zolnowski, D Quietzsch, P Grabowski, B Cremer, S Maasberg, U-F Pape, H-H Mueller, TM Gress, A Rinke, The Members Of The German Net Registry  11  2022 May 31;14(11):2718. doi: 10.3390/cancers14112718.

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report Reutter T, Fassunke J, Püsken M, Weber JP, Binot E, Eisert A, Fischer R, Nogova L, Riedel R, Schaufler D, Scharpenseel H, Scheffler M, Schulz H, Waldschmidt DT, Zander T, Merkelbach-Bruse S, Schirmacher P, Büttner R, Wolf J, Michels S. JCO Precis Oncol. 2023 Apr;7:e2200467. doi: 10.1200/PO.22.00467. PMID: 37079858.

Lebensqualität von Patienten mit metastasiertem RAS-Wildtyp Kolorektalkarzinom: Ergebnisse der laufenden, nicht interventionellen Studie VALIDATE. N Marschner, J Uhlig, L Jacobasch, L Müller, A Schuch, L Serrer, M Reiser, D Semsek, T Göhler, R de Buhr, HU Siebenbach, P Stübs, J Schröder, A Köhler, K Potthoff. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Die prospektive, intersektorale Registerplattform AZURITE: aktuelle Behandlungsrealität des metastasierten kolorektalen Karzinoms in Deutschland. Michl M, Kullmann F, Schnell R, Marschner P, von der Heyde E, Dörfel S, Decker T, Nusch A, Wetzel N, de Buhr R, Kruggel L, Jänicke M, Potthoff K, Graf N, Neumann JH, Stintzing S, AZURITE Registry Platform. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Therapieverläufe der adjuvanten Chemotherapie beim kolorektalen Karzinom im Stadium II und III. Real-World-Daten eines großen ambulanten Patienten-Registers. Schelhas M, Gökkurt E, Kratz-Albers K, Wirecky J, Müller-Hagen S, Schnell R, Reschke D, Borchhardt J, Reichelt R, Hegewisch-Becker S, Stein A. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Ergebnisse der deutschen, nicht-interventionellen REALITY-Studie: Lebensqualität von Patienten mit chronisch lymphatischer Leukämie. Weslau M, Schlag R, Heinrich B, Grosch HW, Krampe S, Dörfel S, Schulz H, Gerhardt A. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie in Deutschland - AIO-TRK-0315. Eberhardt W, Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, Jänicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Verlauf der Fatigue (FACIT-F) bei Immunthrombozytopenie (ITP) unter der Behandlung mit Eltrombopag - Ergebnisse der 5. Interimsanalyse der deutschen nichtinterventionellen Studie RISA. Meyer O, Schlag R, Strauch T, Fleischmann B, Reiser M, Kämpfe D, Behlendorf T, Weslau M, von der Heyde E, Dörfel S, Willy C, Strauch M. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Behandlungssequenzen bei Patienten mit metastasiertem Adenokarzinom des Magens und des ösophago-gastralen Übergangs: Ergebnisse aus der deutschen Registerplattform SAPHIR. Dechow T, Lorenzen S, Potthoff K, von der Heyde E, Dörfel S, Binninger A, Siebenbach HU, Jänicke M, Zahn MO, Nusch A, Schulz H, Reinacher-Schick A, Lordick F. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Register zum Myelodysplastischen Syndrom der NIHO: erste Ergebnisse der Endauswertung. Steinmetz T, Heinz M, Schulte C, Sauer A, Liersch R, Tesch H, Moorahrend E, Heßling J, Reiser M, Schmitz S. Oncol Res Treat 2022;45(suppl 2):140 - DGHO 10/2022 Wien

Second-line Therapien von Patientinnen mit frühem Progress unter DCK4/6-Inhibitoren in der first-line - Daten aus der deutschen Registerplattform OPAL. Marschner N, Harbeck N, Thill M, Stickeler E, Zaiss M, Nusch A, Rauh J, Schulz H, Engelken K, Kruggel L, Jänicke N, Zahn MO, Wöckel A, Welt A, Decker T, OPAL registry platform. Oncol Res Treat 2022;45(suppl 2):115 - DGHO 10/2022 Wien

Zweite Interimsanalyse zu INFINITY - ein Register zur Entscheidungsfindung in der Biomarker-basierten Präzisionsonkologie und deren klinische Bedeutung.Martens U, Schröder J, Sellmann L, Reiser M, Frank-Gleich S, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Woerner S, Zacharias S, Marschner N, Kasenda B, Vannier C. Oncol Res Treat 2022;45(suppl 2):13 - DGHO 10/2022 Wien

Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany. Reiser M, Josten K, Dietzfelbinger H, Seesaghur A, Schill M, Hippenmeyer J, Welslau M: Acta Haematol 2022;145:394-403

Awareness and use of psychosocial care among cancer patients and their relatives - a comparison of people with and without a migration background in Germany. S Singer, N Riccetti, I Hempler, M Fried, J Riera Knorrenschild, L Kalie, M Merbach, M Reiser, F Mosthaf, V Heidt, K Hermes‑Moll. J Cancer Res Clin Oncol 2022 Jun 11:1–13

Integrated, cross‑sectoral psycho‑oncology (isPO): A new form of care for newly diagnosed cancer patients in Germany.  M Kusch, H Labouvie, V Schiewer, N Talalaev, JC Cwik, S Bussmann, L Vaganian, AL Gerlach, A Dresen, N Cecon, S Salm, T Krieger, H Pfaff, C Lemmen, L Derendorf, S Stock, C Samel, A Hagemeier, M Hellmich, B Leicher, G Hultenschmidt, J Swoboda, P Haas, A Arning, A Gottel, K Schwickerath, U Graeven, S Houwaart, H Kerek, HC Bodden, S Krebs, C Muth, C Hecker, M Reiser, C Mauch, J Benner, G Schmidt, C Karlowsky, G Vimalanandan, L Matyschik, L Galonska, A Francke, K Osborne, U Nestle, M Baumer, K Schmitz, J Wolf, M Hallek. BMC Health Services Research 2022, 22:543

Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany. M Reiser, KM Josten, H Dietzfelbinger, A Seesaghur, M Schill, J Hippenmeyer, M Welslau M. Acta Haematologica 145/1, January 2022

2021

Cytoreductive treatment in real life: a chart review analysis on 1440
patients with polycythemia vera. CC Crodel, K Jentsch‑Ullrich, M Reiser, L Jacobasch, A Sauer, H Tesch, T Ulshöfer, R Wunschel, F Palandri, FH Heidel.
J Cancer Res Clin Oncol online 22.11.2021              

CRISP Registry Group. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M. Lung Cancer. 2021 Feb;152:174-184

Interim results of the non-interventional study VALIDATE - 1st-line Panitumumab plus Folfiri or Folfox for patients with RAS wildtype metastastic colorectal cancer in Germany. J Uhlig, J Potenberg, D Semsek, P Stübs, C Fichter, A Köhler, L Müller, M Reiser, HU Siebenbach, T Göhler, L Jacobasch, V Kächele, B Timm, K Potthoff, N Marschner. ESMO Congress September 2020, Posterrnumber: 457P 

First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study. T Dechow, J Riera-Knorrenschild, B Hackanson, J Janssen, H Schulz, M Chiabudini, L Fischer von Weikersthal, S Budweiser, A Nacke, D Taeuscher, M Welslau, K Potthoff. Cancer Med 2021, 10(22):8127-8137

Routine care of patients with Multiple Myeloma (MM) 01/2019-12/2020 not suitable for high-dose melphalan therapy followed by autologous stem cell transplantation (ASCT). R Weide, J Mohm, M Klausmann, H Linde, DH Mainka, T Steinmetz, M Hensel, P Ehscheidt, R Schnell, S Dörfel, L Müller, B Schmidt, M Maasberg, O Burkhard, S Feiten. DGHO 2021 Abstract Book

Diagnosis, treatment and prognosis of patients with low-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) in routine care 01/2010-06/2020. R Weide, O Burkhard, T Steinmetz, R Schnell, L Müller, M Maasberg, M Hensel, S Feiten. DGHO 2021 Abstract Book

Absetzversuche nach TKI-Therapie bei Patienten mit chronischer myeloischer Leukämie außerhalb von klinischen Studien: Zwischenergebnisse der Epidemiologischen Studie zur Versorgungslage von CML-Patienten in Deutschland (CML VI). K Kohlbrenner, N Galuschek, A Fabarius, M Reiser, K Fenchel, E Eßeling, T Göhler, RB Kühn, R Depenbusch, I Azeh, UR Kleeberg, R Hansen, M Hänel, J Anhuf, P Jehner, GM Baerlocher, TH Brümmendorf, D Heim, SW Krause, P le Coutre, A Neubauer, D Niederwieser, H Tesch H, A Hochhaus, R Hehlmann, S Saußele. DGHO 2021 Abstract Book

Effectiveness and safety of Romiplostim in patients with newly diagnosed, persistent and chronic primary immune-thrombocytopenia in german routine clinical practice: The observational PLATEAU Study. M Reiser, KM Josten, H Dietzfelbinger, A Seesaghur, M Schill, J Hippenmeyer, M Welslau . EHA Library 06/09/21; 324878; EP1157

Real-life results from the prospective QOLIXANE trial of the platform for outcome, quality of life and translational research on pancreatic cancer (PARAGON) registry.SE Al-Batran, RD Hofheinz, A Reichart, C Pauligk, R Schlag, GM Siegler, H-G Hoeffkes, H Schulz, W Blau, N Hormann, J Trojan, O Waidmann, D Pink, H Messmann, V Kunzmann, A Vogel, TJ Ettrich, C Schoenherr, M Schaaf, G zur Hausen, TO Goetze. Journal of Clinical Oncology, Volume 38/15, Supplement Meeting Abstract 2020 ASCO

Clinical Research platform into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315 (A-122).  B Passlick, M Stuschke, A Gröschel, P Christopoulos, M Reck, C Grah, A Groth, A Hipper, M Chiabudini, A Fleitz, M Jänicke, L Spring, D Christoph, C Bernhardt, M Reiser, MO Zahn, M Sebastian, F Griesinger, M Thomas, W Eberhardt. 30. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie 22.-24. September 2021, Erfurt

Welche psychoonkologischen Versorgungserfahrungen und -bedürfnisse haben Krebspatient*innen mit Migrationsgeschichte und deren Angehörige? S Singer, N Riccetti, I Hempler, R Fuchs, M Reiser, M Fried, V Heidt, K Hermes-Moll. 19. Jahrestagung der Arbeitsgemeinschaft für Psychoonkologie (PSO)23. bis 25. September 2021 - Abstract-ID 88

 Lebensqualitätsdaten von Patienten mit metastasiertem Kolorektalkarzinom, die mit Trifluridin/ Tipiracil behandelt wurden. M Karthaus, A Kretzschmar, M Welslau, J Riera-Knorrenschild, F Kaiser, H Pelz, T Ettrich, U Lindig, H Schulz, L Fischer von Weikersthal, J Kisro, M de Wit, S Wiebe, M Koenigsmann, R Mahlberg, S Fuxius, I Stehle, S Kubicka, MK Schuler, E Schnoy, J Rüssel, T Graefe, F Mayer, ML Berres, T Kubin, V Heinemann, on behalf of the TALLISUR Group. DGHO 2021 Abstract Poster 317

Discontinuation of tyrosine kinase inhibitor therapy in CML patients outside of clinical trials: Interim results of the German CML VI trial. Kohlbrenner K, Galuschek N, Fabarius A, Reiser M, Fenchel K, Eßeling E, Göhler T, Kühn RB, Depenbusch R, Azeh I, Engel E, Hansen R, Hänel M, Anhuf J, Jehner P, Abu Samra M, Ritter M, Gattermann N, Pelz H, Fuxius S, Oswald B, Baerlocher GM, Brümmendorf TH, Heim D, le Coutre P, Burchert A, Niederwieser D, Tesch H, Hofmann WK, Hochhaus A, Hehlmann R, Saußele S. DGHO 2021 Abstract Poster V157

Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Erste Real-World Evidence zu NSCLC Stadium II und III in Deutschland - AIO-TRK-0315. Eberhardt WEE, Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn MO, Sebastian M, Griesinger F, Thomas M, CRISP Registry Group. DGHO 2021 Abstract Poster V288

Patienten mit RAS-mutiertem metastasiertem kolorektalem Karzinom - Daten aus der klinischen Routine von über 1000 Patienten aus dem Tumorregister Kolorektales Karzinom (TKK). Schnell R, Dörfel S, Bernhardt C, Eggers E, Fruehauf S, Maintz C, Behringer J, Hof A, Wetzel N, Kruggel L, Potthoff K, TKK registry group. DGHO 2021 Abstract Vortrag V65

2020

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study. CB Westphalen, T Kukiolka, B Garlipp, L Hahn, M Fuchs, P Malfertheiner, M Reiser, F Kütting, V Heinemann, A Beringer, DT Waldschmidt. BMC Cancer (2020) 20:155

First interim results from Hyperion, a non-interventional study analysing the effectiveness of atezolizumab (atezo) monotherapy for locally advanced or metastatic non-small cell lung cancer (mNSCLC) after prior chemotherapy (CTx). Heigener D, Geßner C, Nusch A, Schichtl T, Schütte W, Hammerschmidt S, Henschke S, Schumann C, Reck M, Schulz H, Koszinowski S, Reinmuth N. DGHO Jahrestagung 2020 Abstract Book

ENLARGE Lung: Observational data on overall survival, safety and quality of life of 882 patients with locally advanced or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC) treated with nivolumab in Germany. Schumann C, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Liersch R, von der Heyde E, Waldenberger D, Sebastian M. DGHO Jahrestagung 2020 Abstract Book

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with NSCLC: final results from the non-interventional study NADIR. Geßner C, Lück A, Schulz H, Losem C, Dresemann G, Grebhardt S, Harde J, Marschner N, Hipp J, Potthoff K. DGHO Jahrestagung 2020 Abstract Book

First results from INFINITY - A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice. Martens U, Reiser M, Schirrmacher-Memmel S, Sellmann L, Decker T, Schneeweiss A, Schuler M, Bengsch F, Vannier C, Potthoff K, Marschner N, Kasenda B. DGHO Jahrestagung 2020 Abstract Book

Changes in treatment of patients with multiple myeloma in Germany - results from the MYRIAM registry. Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H. MYRIAM-Studiengruppe DGHO Jahrestagung 2020 Abstract Book

Influence of the treatment of immune thrombocytopenia (ITP) with Eltrombopag on the fatigue symptoms of ITP patients - Results of the third interim analysis of the German non-interventional study RISA. Meyer O, Stauch M, Kämpfe D, Schlag R, Reiser M, Stauch T, von der Heyde E, Josting A, Plath M, Ballerstädt N, Stark-Lorenzen P, Scheibenbogen C. DGHO Jahrestagung 2020 Abstract Book

Prognosis in patients with advanced pancreatic cancer and effectiveness of 1st-line treatments - a prognostic and comparative effectiveness study using propensity score weighting for patients treated with Gem+Nab vs. FOLFIRINOX from the TPK registry Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach S H, Kreher S, Binninger A, Chiabudini M, Jänicke M, Marschner N. DGHO Jahrestagung 2020 Abstract Book

Treatment patterns of patients with BRAF-mutant metastatic colorectal cancer: Results from the German Tumor Registry Colorectal Cancer (TKK Registry). Zahn M-O, Dörfel S, Schnell R, Wolf T, Vehling-Kaiser U, Kruggel L, Jänicke M, Wetzel N, Marschner N, TKK registry group. DGHO Jahrestagung 2020 Abstract Book

Treatment outcome of patients with diffuse large B-cell lymphoma (DLBCL) in routine care who received standard chemoimmunotherapy with MabThera® compared to patients treated with a rituximab biosimilar in first line therapy. Weide R, Burkhard O, Steinmetz T, Schnell R, Vehling-Kaiser U, Koenigsmann M, Ehscheidt P, Müller L, Otremba B, Wierecky J, Tamm I, Hensel M, Knoblich J, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, Köppler H, Lutschkin J, Lutz C, Thomalla J, van Roye C, Heymanns J. DGHO Jahrestagung 2020 Abstract Book

Treatment reality of patients with multiple myeloma 1995-2018 in Germany Weide R, Steinmetz T, Schnell R, Maasberg M, Müller L, Burkhard O, Braun U, Ehscheidt P, Tamm I, Rendenbach B, Feiten S. DGHO Jahrestagung 2020 Abstract Book

FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Nogova L, Malchers F, Hillmer A M, Merkelbach-Bruse S, Pinto A, Scheel A H, Siemanowski J, Ueckeroth F, Scheffler M, Hummel H-D, Kern J, Wermke M, Kolbe M, Grohe C, Stratmann J, Sebastian M, Trummer A, Weber J-P, Westphal T, Michels S, Koleczko S, Sueptitz J, Keser E, Kron A, Riedel R, Abdulla D S Y, Zadoyan G, Sweiti H, Santiago-Walker A, Rothe A, Draube A, Sandler A, Rodermann E, Linck D, Thomas R K, Büttner R, Wolf J. DGHO Jahrestagung 2020 Abstract Book

KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Scheffler M, Nogova L, Michels S, Holzem A, Chanra T, Abdulla D S Y, Koleczko S, Merkelbach-Bruse S, Fassunke J, Kron A, Scheel A H, Ihle M A, Heydt C, Westphal T, Weber J-P, Fischer R N, Riedel R, Kaminsky B, Draube A, Rothe A, Kambartel K-O, Hillmer A, Büttner R, Wolf J. DGHO Jahrestagung 2020 Abstract Book

Disease management of patients with immune thrombocytopenie - results of a representative retrospective survey in Germany. AS Kubasch, J Kisro, J Heßling, H Schulz, HJ Hurtz, M Klausmann, A Ehrnsperger, U Platzbecker. EHA 2020 Abstract Book

2019

Ibrutinib versus Placobo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukomiaa (CLL):Primary endpoint results of the phase 3 double-blind randomized CLL12 TRIAL. Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. EHA Library. Jun 16, 2019

Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany. Carl C Crodel, Kathleen Jentsch-Ulrich, Lutz Jacobasch, Philipp Kiewe, Jens Kisro, Jörg Lipke, Siegfried W Prenninger, Marcel Reiser, Regine Wunschel, Andreas Hochhaus, Florian H Heidel. Blood (2019) 134 (Supplement_1): 1672

Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: a thorough gender-specific analysis using the WoMo score. Maria R Gaiser, Sylvie Lorenzen, Kirsten Merx, Jörg Trojan, Janja Ocvirk, Thomas J Ettrich  Salah-Eddin Al-Batran, Holger Schulz, Nils Homann, Hans-Peter Feustel, Michael Schatz, Melanie Kripp, Nadine Schulte, Steffen Heeger, Soetkin Vlassak, Winfried Koch, Ralf-Dieter Hofheinz. Cancer Med 2019 Aug;8(9):4169-4175

Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind, placebo-controlled randomized CLL12 trial. Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink A-M, Kreuzer K-A, Vehling-Kaiser U, Tausch E, Müller L, Eckart M J, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner C-M, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. Deutsche CLL Studiengruppe DGHO Jahrestagung 2019 Abstract Book

Treatment of immunethrombocytopenia (ITP) with Revolade - results of the 2nd interim analysis of the German non-interventional trial RISA. Meyer O, Stauch M, Kämpfe D, Schlag R, Reiser M, Dörfel S, von der Heyde E, Josting A, Lipke J, Ballerstädt N, Michels K. DGHO Jahrestagung 2019 Abstract Book

Implementation of a molecular tumor board in clinical decision making at the medical center University of Freiburg. Hoefflin R, Wehrle J, Becker H, Reiser M, Metzger P, Hess M, Mehmed L, Rawluk J, Heiland D H, Erbes T, Schaefer H, Heeg S, Hettmer S, Boeker M, Werner M, Duyster J, Peters C, Botzenhart E M, Brummer T, Fritsch R, Dierks C, Miething C, Illert L, Lassmann S, Boerries M, von Bubnoff N. DGHO Jahrestagung 2019 Abstract Book

2nd-line treatment and outcome in patients with locally advanced or metastatic pancreatic cancer - data from the TPK clinical cohort study. Hegewisch-Becker S, Lerchenmüller C, Reiser M, Zacharias S, Hamm D, Jaenicke M, Marschner N, for the TPK Registry Group. DGHO Jahrestagung 2019 Abstract Book

Patient-reported outcomes (PRO) on the use of Ruxolitinib (RUX) in myelofibrosis (MF): data from the JAKoMo phase IV trial. Koschmieder S, Schulte C, Reiser M, Hansen R, Koenigsmann M, Geer T, Gröschl B, Großer S, Koehler M. DGHO Jahrestagung 2019Abstract Book

Patients with metastatic non-small cell lung carcinoma and targetable oncogenic molecular alterations in Germany. Treatment and first outcome data from the prospective German registry CRISP (AIO-TRK-0315). Griesinger F, Eberhardt W E E, Nusch A, Reiser M, Zahn M-O, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Waller C F, Reck M, Christopoulos P, Sebastian M, Thomas M. DGHO Jahrestagung 2019 Abstract Book

ith multiple myeloma in Germany - first patient-reported outcomes data from MYRIAM, the prospective, national, intersectoral cohort study for treatment and outcome of myeloma patients. Engelhardt M, Knauf W, Lipke J, Zahn M-O, Dörfel S, Bittrich M, Reiser M, Sauer A, Aubele P O, La Rosée P, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H. MYRIAM-Studiengruppe DGHO Jahrestagung 2019 Abstract Book

Real-world evidence: interim analysis of efficacy in 628 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) treated with Nivolumab after prior chemotherapy in a national, prospective, non-Interventional study (ENLARGE-Lung). Sebastian M, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Schulte C, Wünsch V, Schumann C. DGHO Jahrestagung 2019 Abstract Book

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with long-acting G-CSF in patients treated with chemotherapy in Germany: results of the epidemiological cross-sectional survey “G-CSF Day”. Egerer G, Uleer C, Klausmann M, Lück A, Schröder J, Schulz H, Fichter C, von der Heyde E, Voss P, Worth G, Burbeck M, Sahlmann J, Potthoff K. DGHO Jahrestagung 2019 Abstract Book

Treatment reality of patients with multiple myeloma 2012-2017 in Germany Weide R, Burkhard O, Braun U, Steinmetz T, Ehscheidt P, Schnell R, Tamm I, Müller L, Feiten S. DGHO Jahrestagung 2019 Abstract Book

Patients with marginal zone lymphoma: characteristics, treatment reality and outcome data from the German prospective TLN Registry. Knauf W, Abenhardt W, Koenigsmann M, Maintz C, Sandner R, Zahn M-O, Schnell R, Houet L, Tech S, Jänicke M, Marschner N. TLN-Studiengruppe DGHO Jahrestagung 2019 Abstract Book

2018

Disease management of patients with immune thrombo-cytopenia - Results of a representative retrospective survey in Germany. Kubasch AS Kisro J, Heßling J, Schulz H, Hurtz HJ, Klausmann M, Ehrnsperger A, Platzbecker U. EHA Library. annual congress E. Jun 11, 2018; 219320; Abstract PF675

Personalized clinical decision making through implementation of a molecular tumorboard at the comprehensive cancer center Freiburg. Hoefflin R, Geißler AL, Fritsch R, Claus R, Wehrle J, Metzger P, Reiser M, Mehmed L, Fauth L, Heiland DH, Erbes T, Stock F, Csanadi A, Miething C, Weddeling B, Meiss F, von Bubnoff D, Dierks C, Ge I, Brass V, Heeg S, Schäfer H, Boeker M, Rawluk J, Botzenhart EM, Kayser G, Hettmer S, Busch H, Peters C, Werner M, Duyster J.1, Brummer T, Börries M, Lassmann S, von Bubnoff N. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Safety and efficacy of the thrombopoietin receptor agonist Eltrombopag in patients with chronic Immune Thrombocytopenia (cITP) in routine healthcare – results of the 1st interim analysis of the non-interventional study RISA. Meyer O, Reiser M, Dörfel S, Schlag R, Kämpfe D, Welslau M, Losem C, Zahn MO, von der Heyde E, Ehrnsperger A. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Survival of patients with metastatic solid tumours who received their treatment in community-based oncology group practices is longer compared to registry data and comparable to randomized controlled trials (RCT). Weide R, Chakupurakal G, Feiten S, Friesenhahn V, Kleboth K, Köppler H, Lutschkin J, Thomalla J, van Roye C, Oswald B, Reimann B, Lorentz C, Rendenbach B, Laubenstein HP, Braun U, Hünermund K, Ehscheidt P, Reiser M, Heymanns J. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315). Griesinger F, Eberhardt W, Nusch A, Reiser M, Bernhardt C, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Rittmeyer A, Bischoff H, Waller CF, Sebastian M, Thomas M. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Real life data of 601 patients from the QoliXane pancreatic cancer study. Schönherr C, Götze TO, zur Hausen G, Reichart A, Pauligk C, Schlag R, Siegler G, Dörfel S, Aldaoud A, Hahn L, Schubert J, Zahn MO, Höffkes HG, Reiser M, Koenigsmann M, Blau W, Uhlig J, Homann N, Trojan J, Al-Batran SE. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Carfilzomib in combination with lenalidomide and dexamethasone or carfilzomib in combination with dexamethasone alone in patients with multiple myeloma who have received at least one prior therapy: Interim results of the non-interventional CARO study. Knauf W, Ammon A, Uhlig J, Merling M, Hurtz HJ, Vannier C.4, Schulz H, Marschner N, Riedt T, Potthoff K. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study. Dechow T, Riera-Knorrenschild J, Schulz H, Janssen J, Chiabudini M, Koszinowski S, Potthoff K, Runkel E. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Prospective multicenter analysis of health status and quality of life in patients with immunodeficiencies receiving intravenous immunoglobulin G (IgG) substitution in oncology group practices in Germany (LQ-IgG). Weide R, Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn M, Wierecky J, Hünermund K, Hensel M, Klausmann M, Hartenstein R, Ehscheidt P, Feiten S. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf®) in patients with metastatic colorectal cancer (CRC) in clinical routine use Cao J, Wiesweg M, Fuchs M, Stein A, Karthaus M, Lettmaier S, Kretzschmar A, Draube A, Ettrich T, Rüssel J, Müller C, Rafiyan MRR, Borchert K, Schuler M, Kasper S. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. Knauf W, Ammon A, Uhlig J, Merling M, Hurtz HJ, Vannier C, Schulz H, Marschner N, Riedt T, Potthoff K. Blood 2018 132:5662

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN). Isfort S, Stegelmann F, Klausmann M, Schulz H, Hollburg W, Al-Ali HA, Goethert JR, Heidel FH, Maintz C, Haenel M, Platzbecker U, Hansen R, Keszei A, Gecht J, Kricheldorf K, Kaifie A, Crysandt M, Gezer D, Griesshammer M, Brümmendorf TH, Döhner K, Koschmieder S. Blood 2018 132:4292

Real life data of 601 patients from the QoliXane pancreatic cancer study. Schoenher C, Goetze TO, zur Hausen G, Reichart A, Pauligk C, Schlag R, Siegler GM, Doerfel S, Aldaoud A, Hahn L, Schubert JEA, Zahn MO, Hoeffkes HG, Reiser M, Koenigsmann M, Blau W, Uhlig J, Homann N, Trojan J, Al-Batran SE. Journal of Clinical Oncology 2018 36:15_suppl, e16248-e16248

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study. Schulz H, Janssen J, Strauss UP, Langen M, Dworschak KU, Fiala-Buskies S, Bokemeyer C, on behalf of the RECORA Investigators. ASCO GI Kongress San Francisco Abstract Januar 2018

Real Life Data of 601 patients from the QoliXane Pancreatic Cancer Study. Schönherr C, Götze TO, zur Hausen G, Reichart A, Pauligk C, Schlag R, Siegler G, Dörfel S, Aldaoud A, Hahn L, Schubert J, Zahn MO, Höffkes HG, Reiser M, Koenigsmann M, Blau W, Uhlig J, Homann N, Trojan J, Al-Batran SE. DHGO Abstract 2018

2017

Final results from an observational study (PLATEAU) of adult patients treated with romiplostim for primary immune thrombocytopenia (ITP) in routine clinical practice in Germany. Reiser M, Welslau M, Josten K, Dietzfelbinger H, Kuhn A.EHA 2017 Abstract E1449

Retrospective analysis of the disease management of patients with immune thrombocytopenia. Platzbecker U, Heßling J, Hurtz HJ, Schulz H , Josting A, Hauch U, von der Heyde E, Dengler J, Tummes D, Plath M, Becker M, Welslau M, von Depka Prondzinski M. DGHO Poster 30.09.2017

Molecular testing and first-line treatment of patients with NSCLC. First results from the German CRISP study (AIO-TRK-0315). Griesinger F, Eberhardt WEE, Nusch A, Reiser M , Losem C, Ketzler-Henkel S, Zahn M-O, Marschner N, Jaenicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, de Wit M, Metzenmacher M, Waller CF, Kern J, Weichert W, Sebastian M, Thomas M. WLCC Abstract 2017, DKK Abstract 2017, DGP Abstract 2017

Molecular testing, frequency of molecular alterations and first-line treatment of patients with non-small cell lung carcinoma (NSCLC) in Germany. First results from the prospective German Registry CRISP (AIO-TRK-0315) Griesinger F.Eberhardt W.E.Nusch A. Reiser M .Losem C.Ketzler- Henkel S. Zahn M.-O Marschner N.Jänicke M.Fleitz A.Spring L.Sahlmann J. Hipper A.Karatas A.de Wit M.Metzenmacher M.Waller C.F.Kern J. Weichert W.Sebastian M.Thomas M. DGHO abstract Oncol Res Treat 2017;40(suppl 3): 1-168 V508

Cisplatin vs. carboplatin in routine treatment of advanced non-small cell lung cancer - results from the prospective German TLK cohort study Verschuer U. Schnell R .Zahn M.-O.Eggert J.Binninger A.Spring L.Jänicke M. Marschner N. Oncol Res Treat 2017;40(suppl 3): 1-168 V718

Metastatic Pancreatic Cancer: real Life Data from the German Quality of Life and translational research on pancreatic cancer study (QoliXane) Reichart A. Al-Batran S.-E. Schönherr C. Zur Hausen G. Pauligk C. Schöttger B. Siegler G. Dörfel S. Aldaoud A. Hahn L. Schubert J. Waidmann O. Trojan J. Höffkes H.-G. Schnell R. Königsmann M. Blau W.Uhlig J.Homann N. Götze T.O. 1 Oncol Res Treat 2017;40(suppl 3): 1-168 P536

High age and high frequency of treatment switch in CML patients outside of clinical trials: interim results of the German CML VI trial Kohlbrenner K. 1 , Arnecke L. 1 , Fabarius A. 1 , Bieber R. 1 , Voskanyan A., Reiser M . 2 , Fenchel K. 3 , Schmidt E. 4 , Göhler T. 5 , Kühn R.B. 6 , Depenbusch R. 7 , Azeh I. 8 , Kleeberg U.R. 9 , Hansen R. 10 , Hänel M. 11 , Anhuf J. 12 , Jehner P. 13 , Baerlocher G.M. 14 , Brümmendorf T.H. 15 , Ehninger G. 16 , Hasford J. 17 , Heim D. 18 , Hossfeld D.K. 19 , Kolb H.-J. 20 , Krause S.W. 21 , le Coutre P. 22 , Nerl C. 23 , Neubauer A. 24 , Niederwieser D. 25 , Tesch H. 26 , Hochhaus A. 27 , Hehlmann R. 1 Oncol Res Treat 2017;40(suppl 3): 1-168 V763

Efficacy of different immunoglobulin doses in the prevention of severe and serious infections in patients with secondary immunodeficiencies - results from a multicenter observational study with Privigen® Ehlers H.-U. 1 , Innig G. 2 , Otremba B. 3 , Plath M. 4 , Slawik H.R. 4 , Â¥. 5 , Weide R. 6 , Pfründer D. Reiser M. 2 , Fenchel K. 3 , Schmidt E. 4 , Göhler T. 5 , Kühn R.B. 6 , Depenbusch R. 7 , Azeh I. 8 , Kleeberg U.R. 9 , Hansen R. 10 , Hänel M. 11 , Anhuf J. 12 , Jehner P. 13 , Baerlocher G.M. 14 , Brümmendorf T.H. 15 , Ehninger G. 16 , Hasford J. 17 , Heim D. 18 , Hossfeld D.K. 19 , Kolb H.-J. 20 , Krause S.W. 21 , le Coutre P. 22 , Nerl C.   23 , Neubauer A. 24 , Niederwieser D. 25 , Tesch H. 26 , Hochhaus A. 27 , Hehlmann R. 28 , Saußele S. 1 , for the German CML study group Oncol Res Treat 2017;40(suppl 3): 1-168 P846

Correlation between the IgG plasma concentrations and the incidence of infections in patients with chronic lymphocytic leukemia (CLL) under treatment with Privigen® Otremba B. 1 , Haslbauer F. 2 , Reiser M . 3 , Weide R. 4 , Pfründer D. 5 P313 Retrospective analysis of the disease management of patients with immune thrombocytopenia Platzbecker U. 1 , Heßling J. 2 , Hurtz H.-J. 3 , Schulz H . 4 , Josting A. 5 , Hauch U. 6 , von der Heyde E. 7 , Dengler J. 8 , Tummes D. 9 , Plath M. 10 , Becker M. 11 , Welslau M. 12 , von Depka Prondzinski M. Oncol Res Treat 2017;40(suppl 3): 1-168 P577

Bevacizumab (Bev)-based combinations across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC) - interim results from a German non-interventional study (KORALLE) Eggers E. 1 , Uhlig J. 2 , Reichert D. 3 , Wein A. 4 , Schulz H . 5 , Beringer A. 6 , Arnold D. Oncol Res Treat 2017;40(suppl 3): 1-168

Systemic palliative treatment and outcome in later lines in patients with metastatic colorectal cancer - Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK) Schnell R . 1 , Uhlig J. 2 , Eggers E. 3 , Jänicke M. 4 , Fleitz A. 4 , Wetzel N. 4 , Marschner N. 5 , for the TKK registry group Oncol Res Treat 2017;40(suppl 3): 1-168 P587

EHA FINAL RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU) OF ADULT PATIENTS TREATED WITH ROMIPLOSTIM FOR PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE IN GERMANY Author(s): Marcel Reiser , Manfred Welslau , Klaus Josten , Hermann Dietzfelbinger ,Anja Kuhn (Abstract release date: May 18, 2017) EHA Learning Center. Reiser M . EHA May 18, 2017; 181225

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study . Holger Schulz, Jan Janssen, Uwe P. Strauss , Markus Langen , Marcel Frey , Sabine Fiala-Buskies , Journal of Clinical Oncology 35, no. 4_suppl (February 2017) 769-769.

2016

Correlation between efficacy of the intravenous immunoglobulin preparation IgPro10 and IgG plasma concentrations achieved in secondary immunodeficiencies (SID). Reiser M, Otremba B, Plath M, Slawik HR, Pfründer D. 17th ESID Meeting (European Society of Immunodeficiencies) Barcelona 2016

Systemic palliative treatment in patients with metastatic colorectal cancer tested for their (K)RAS mutation status - Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK) Zahn M.O. 1 , Schnell R . 2 , Karcher A. 3 , Schnitzler M. 4 , Wetzel N. 4 , Fleitz A. 4 , Marschner N. 5 , for the TKK registry group Oncol Res Treat 2016;39(suppl 3):1-294: V171

Overall survival of 4865 patients with metastatic solid tumours treated in German routine practice - combined results from four prospective, multicentre cohort studies Marschner N. 1 , Potthoff K. 2 , Schnell R . 3 , Tesch H. 4 , Zahn M.-O. 5 , Hegewisch- Becker S. 6 , Jänicke M. 2 , iOM-Registry group Onkol. Schwerpunktpraxis HH Eppendorf, Hamburg, Germany Oncol Res Treat 2016;39(suppl 3):1-294: V174

Treatment and survival of patients with advanced pancreatic cancer in community-based oncology group practices 2012 - 2015 Weide R. 1 , Burkhard O. 2 , Reiser M . 3 , Ehscheidt P. 4 , Feiten S. Oncol Res Treat 2016;39(suppl 3):1-294: P868

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with lung cancer: results from an interim analysis of the non-interventional study NADIR Potthoff K. 1 , Lück A. 2 , Frost N. 3 , Losem C. 4 , Weide R. 5 , Schulz H. Oncol Res Treat 2016;39(suppl 3):1-294:P949

Parenteral nutrition support for patients with advanced pancreatic cancer - interim results from the sub-project "PaNut" of the Pancreatic Cancer Registry (TPK) Hegewisch-Becker S. 1 , Wolf T. 2 , Reiser M . 3 , Scheiner-Sparna R. 4 , Hamm D. 4 , Marschner N. 5 , for the TPK Registry Group 1 Onkologische Schwerpunktpraxis Hamburg Eppendorf, Hamburg, Germany, 2 BAG/Onkologische Gemeinschaftspraxis, Dresden, Germany, 3 Praxis internistischer Onkologie und Hämatologie, Köln, Germany, 4 iOMEDICO, Freiburg i. Br., Germany, 5 Praxis für Interdisziplinäre Onkologie & Hämatologie, Freiburg i. Br., Germany Oncol Res Treat 2016;39(suppl 3):1-294: P869 Â Â

Utilisation of facilitated subcutaneous immunoglobulin treatment (HYQvia) in patients with SID: Preliminary data from the SIGNS registry Reiser M. 1 , Fasshauer M. 2 , Borte M. 2 , Baumann U. 3 , Gold R. 4 , Pittrow D. 5 , Huscher D. 6 , Stangel M. 7 , Sommer C. 8 , Otto G.P. 9 , Hensel M. Oncol Res Treat 2016;39(suppl 3):1-294: P956

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with Non-Hodgkin-Lymphoma (NHL): results from an interim analysis of the non- interventional study NADIR Fietz T. 1 , Wolff T. 2 , Schulz H . 3 , Sandner R. 4 , Reichert D. 5 , Hurtz H.-J. 6 , Müller J. 7 , Grebhardt S. Oncol Res Treat 2016;39(suppl 3):1-294: P950

2015

Privigen® in secondary immunodeficiencies - interim analysis of a multicenter non-interventional study in Germany Plath M.1, Slawik H.R.1, Reiser M .2, Otremba B.3, Pfründer D. Oncol Res Treat 2015;38(suppl 5):1-288 P253 -

Cytogenetic and molecular responses in German patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY) Repp R.1, Hehlmann R.2, Linde H.3, Reiser M .4, Tesch H.5, Foreman A.6, Schreiner L.7, Hillig G. Oncol Res Treat 2015;38(suppl 5):1-288 P451 -

Application of Rituximab in Maintenance (RIM) therapy in Follicular Lymphoma (FL) in routine clinical practice - final results of a non-interventional study (NIS) in Germany Dührsen U.1, Dieing A.2, Reiser M .3, Prange-Krex G.4, Jentsch-Ullrich K.5, Lück A.6, Porowski P.7, Schwinger U.8, Broszeit-Luft S.9, Klawitter S.10, Krumm K.10, Lerchenmüller C. Oncol Res Treat 2015;38(suppl 5):1-288 P473

Implementation of RAS testing in patients with metastatic colorectal cancer in German outpatient cancer centers - data from the clinical TKK registry Schnell R .1, Trarbach T.2, Broszeit-Luft S.3, Musch R.4, Frank M.2, Kopfmann S.2, Jänicke M.2, Marschner N.5, for the TKK Registry Group Oncol Res Treat 2015;38(suppl 5):1-288 V394

Relevance of neo- or adjuvant pretreatment in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab as first-line treatment - data from the prospective TKK registry Schnell R. 1, Trarbach T.2, Broszeit-Luft S.3, Musch R.4, Wetzel N.2, Kopfmann S.2, Jänicke M.2, Marschner N.5, for the TKK Registry Group
Oncol Res Treat 2015;38(suppl 5):1-288 V395

The need for psychooncological support in breast cancer patients: A longitudinal study. Ralf R. Reichelt , Christian M. Kurbacher , Roland Schnell Journal of Clinical Oncology 33, no. 15_suppl

SORAVE: Phase I study for the treatment of relapsed solid tumors with the combination of sorafenib and everolimus. Lucia Nogova , Christian Mattonet , Matthias Scheffler , Marc Christiaan Allardt Bos , Masyar Gardizi , Irini Papachristou , Noemi Muthen , Denis Rokitta , Martina Kinzig , Fritz Soergel , Uwe Fuhr , Deniz Kahraman , Carsten Kobe , Kerstin Rhiem , Peter Mallmann , Roland Schnell , Ildiko Katay , Max Schlaak , Markus Dietlein , Juergen Wolf Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2550-2550.

2014

Genotyping upper gastrointestinal cancer in daily clinical care. Thomas Zander , Michael Kloth , Shahram Zoghi , Laura Groneck , Birgit Cremer , Roland Schnell , Marcel Reiser , Jutta Benz , Tom Luedde , Achim Rothe , Yon-Dschun Ko , Andreas Draube , Stefan Paul Moenig , Juergen Wolf , Arnulf H Hölscher , Reinhard Buettner Journal of Clinical Oncology 32, no. 15_suppl

Management of secondary immunodeficiencies with immunoglobulins (IG) under clinical practice conditions: update 2014 Hensel M. 1 , Stangel M. 2 , Gold R. 3 , Borte M. 4 , Faßhauer M. 4 , Pittrow D. 5 , Huscher D. 6 , Baumann U. 7 , Kirch W. 5 , Reiser M . 8 , SIGNS Studiengruppe Oncol Res Treat 2014;37(suppl 5):1-313 P188

Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer - data from the clinical TKK registry Schnell R . 1 , Musch R. 2 , Broszeit-Luft S. 3 , Harde J. 4 , Kopfmann S. 4 , Jänicke M. 4 , Marschner N. Oncol Res Treat 2014;37(suppl 5): 1-313 V332 Â Â

Cancer patient self-assessment of symptoms and complaints, and their computer-assisted documentation Schnell R. , Heirich P., Hellmann M ., Eisenblätter C., Schulz H. pioh Frechen, Frechen, Germany Oncol Res Treat 2014;37(suppl 5): 1-313 P539

Treatment of relapsed/refractory multiple myeloma patients with lenalidomide/dexamethasone in routine clinical practice Schwarzer A. 1 , Frühauf S. 2 , Königsmann M. 3 , Schnell R . 4 , Reeb M. 5 , Heits F. 6 , Tirier C. 7 , Prange-Krex G. 8 , Knauf W. 9 , Bachinger A. 10 , Weiligmann C. 11 , Hoppe G. 11 , Glasmacher A. 12 , Schmidt B. Oncol Res Treat 2014;37(suppl 5): 1-313 P871

RET rearrangement in adenocarcinoma of the lung Michels S. 1 , Schultheis A. 2 , Scheffler M. 1 , Rosner T. 1 , Merkelbach- Bruse S. 2 , Heukamp L. 2 , Engel-Riedel W. 3 , Serke M. 4 , Krüger S. 5 , Benedikter J. 6 , Gerigk U. 7 , Schulte W. 8 , Draube A . 9 , Ko Y.D. 10 , Büttner R. 2 , Wolf J. 1 , Lung Cancer Group Cologne Oncol Res Treat 2014;37(suppl 5): 1-313 V32

PROCAPP: A randomized, open-label phase III trial comparing mapisal and urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot skin reaction (HFSR) in patients (pts) with gastrointestinal (GI) tumors or breast cancer – A study of the AIO Quality of Life Working Group. Deniz Gencer , Andreas Schneeweiss , Holger Schulz , Michael Stahl , Susanna Hegewisch-Becker , Luisa Mantovani Loeffler , Ursula Kronawitter , Georg Bolz , Jochen Potenberg , Salah-Eddin Al-Batran , Ralf Hofheinz Journal of Clinical Oncology 32, no. 15_suppl (May 2014) 9631-9631.

2013

Overall survival of ALK translocation positive NSCLC patients treated with and without crizotinib. A retrospective analysis within the Network Genomic Medicine Bos M. 1 , Gardizi M. 1 , Heukamp L. 2 , Nogova L. 1 , Merkelbach- Bruhse S. 2 , König K. 2 , Zander T. 3 , Schildhaus H.-U. 2 , Fricke R. 4 , Krieg V. 4 , Scheffler M. 1 , Serke M. 5 , Schnell R . 6 , Schulz H. 6 , Töpelt K. 3 , Panse J. 7 , Schmitz S. 8 , Severin K. 9 , Steinmetz T. 9 , Gerigk U. 10 , Brettner S. 11 , Hecker E. 12 , Reiser M. 6 , Katay I. 6 , Kaufmann T. 13 , Ko Y.D. 14 , Buchenroth M. 15 , Kruis W. 16 , Schlesinger A. 17 , Laskowski U. 18 , Maintz C. 19 , Vogt J. 20 , Randerath W.J. 21 , Konrad F. 22 , Hekmat K. 23 , Krüger S. 24 , Kambartel K. 25 , Galetke W. 26 , Hünerlitürkoglu A.-N. 27 , Thomas R. 28 , Büttner R. 2 , Wolf J. 1 , Netzwerk Genomische Medizin Onkologie 2013;36(suppl 7):1-289 V116

Current development of the Network Genomic Medicine in lung cancer Bos M. 1 , Heukamp L. 2 , Gardizi M. 1 , König K. 2 , Merkelbach-Bruhse S. 2 , Zander T. 3 , Scheffler M. 4 , Albus K. 2 , Schildhaus H.-U. 5 , Fassunke J. 5 , Künstlinger H. 5 , Kleine M. 2 , Binot E. 2 , Nogova L. 1 , Mattonet C. 1 , Serke M. 6 , Panse J. 7 , Schnell R . 8 , Schulz H. 8 , Töpelt K. 4 , Schlesinger A. 9 , Krüger S. 10 , Kambartel K. 11 , Reiser M. 12 , Behringer D. 13 , Gerigk U. 14 , Schulte W. 15 , Diet F. 16 , Randerath W.J. 17 , Brettner S. 18 , Ko Y.D. 19 , Buchenroth M. 20 , Benz J. 21 , Severin K. 22 , Schmitz S. 22 , Steinmetz T. 22 , Mainka D. 22 , Dietze L. 22 , Kaufmann T. 23 , Konrad F. 24 , Hekmat K. 25 , Thomas R. 26 , Büttner R. 2 , Wolf J. 1 , Netzwerk Genomische Medizin Onkologie 2013;36(suppl 7):1-289 V603

Current management of secondary immunodeficiency (SID) under clinical practice conditions Hensel M. 1 , Gold R. 2 , Baumann U. 3 , Borte M. 4 , Stangel M. 5 , Fasshauer M. 4 , Pittrow D. 6 , Huscher D. 7 , Kirch W. 6, Reiser M . 8 , SIGNS Study Onkologie 2013;36(suppl 7):1-289 V711

Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer Gardizi M. 1 , Scheffler M. 1 , Bos M. 1 , Geist T. 2 , Heukamp L. 3 , Nogova L. 1 , Töpelt K. 1 , Fernandez-Cuesta L. 4 , Culmann H. 5 , Kaminsky B. 6 , Panse J. 7 , Becker C. 7 , Mattonet C. 1 , Serke M. 8 , Schmitz S. 9 , Schnell R. 1 , Galetke W. 10 , Hekmat K. 1 , Büttner R. 3 , Wolf J. Onkologie 2013;36(suppl 7):1-289 V120

Association of PIK3CA mutations and age with the occurence of second primary lung cancer (SPLC). Marc Christiaan Allardt Bos , Masyar Gardizi , Matthias Scheffler , Lucia Nogova , Thomas Zander , Lukas Carl Heukamp , Hans-Ulrich Schildhaus , Sabine Merkelbach-Bruse , Jana Fassunke , Elke Binot , Andreas Schlesinger , Thomas Geist , Kato Kambartel , Roland Schnell , Holger Schulz , Dirk M. Behringer , Monika Serke , Stephan H. Schmitz , Winfried Randerath , Juergen Wolf Journal of Clinical Oncology 31, no. 15_suppl (May 2013) 1589-1589.

2012

Predictive diagnostics for response to therapy of chemotherapy associated anemia with darbepoetin alfa +/- intravenous iron in cancer patients: PFAD. Â Steinmetz HT, Kuhr K, Hellmich M, Heinz M, Neise M, Mittermüller J, Tessen HW, Reiser M , Severin K, Schmitz S, Tessen W. ESMO Kopenhagen Abstract Oct 2012

Outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab (R) applications given over an extended period (SMARTE-R-CHOP-14 trial of the DSHNHL). Niels Murawski , Gerhard Held , Samira Zeynalova , Carsten Mueller , Viola Poeschel , Andreas Viardot , Mathias Haenel , Ulrich Keller , Marcel Reiser , Marita Ziepert , Norbert Schmitz , Michael Pfreundschuh Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8025-8025.

Evidence for rituximab (R) underdosing in subpopulations of elderly patients with DLBC: Results of the RICOVER-60 study of the DSHNHL. Michael Pfreundschuh , Carsten Mueller , Samira Zeynalova , Gerhard Held , Viola Poeschel , Carsten Zwick , Marcel Reiser , Eva Lengfelder , Hjalmar B. Steinhauer , Christina Limmroth , Norbert Schmitz , Niels Murawski Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8024-8024.

Management of secondary immunodeficiencies with immunoglobulins (IG) under clinical practice conditions. Marcel Reiser , David Pittrow , Martin Stangel , Ralf Gold , Michael Borte , Maria Fasshauer , Wilhelm Kirch , Doerte Huscher , Ulrich Baumann , Manfred Hensel DOI: 10.1200/jco.2014.32.15_suppl.e17596 Journal of Clinical Oncology 32, no. 15_suppl

IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma . Marina Tschaika , Hans-Joachim Schmoll , Jorge Riera-Knorrenschild , Dieter Nitsche , Jorg Trojan , H. Kröning , Fritz Albert Maiwirth , Marcel Reiser , Matthias Schroff , Ekaterina Weith , Manuel Schmidt , Burghardt Wittig Journal of Clinical Oncology Feb 2012

Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNHL . Gerhard Held , Niels Murawski , Marita Ziepert , Viola Poeschel , Carsten Zwick , Marcel Reiser , Sibylla Wilhelm , Tobias Gaska , Michael Heike , Joerg Schubert , Norbert Schmitz , Markus Loeffler , Christian Ruebe , Michael Pfreundschuh , Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8022-8022

Clinical characteristics and natural history of patients with squamous cell lung carcinoma with FGFR1 amplification . Marc Christiaan Allardt Bos , Masyar Gardizi , Lukas Carl Heukamp , Hans-Ulrich Schildhaus , Lucia Nogova , Yon-Dschun Ko , Andreas Schlesinger , Michael Brockmann , Monika Heidi Serke , Ulrich Gerigk , Khosro Hekmat , Erich Stoelben , Marcel Reiser , Walburga Engel-Riedel , Roland Schnell , Stephan H. Schmitz , Konrad Frank , Reinhard Buettner , Juergen Wolf , Thomas Zander Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 1533-1533.

Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network . Masyar Gardizi , Matthias Scheffler , Lukas Carl Heukamp , Marc Christiaan Allardt Bos , Kerstin Albus , Birgit Hayn , Yon-Dschun Ko , Andreas Schlesinger , Michael Brockmann , Monika Heidi Serke , Ulrich Gerigk , Khosro Hekmat , Erich Stoelben , Marcel Reiser , Roland Schnell , Stephan H. Schmitz , Konrad Frank , Reinhard Buettner , Jurgen Wolf , Thomas Zander Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 10526-10526.

Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment. Thomas Zander , Lukas Carl Heukamp , Marc Christiaan Allardt Bos , Jana Fassunke , Christian Mattonet , Sabine Merkelbach-Bruse , Yon-Dschun Ko , Andreas Schlesinger , Michael Brockmann , Monika Serke , Ulrich Gerigk , Khosro Hekmat , Walburga Engel-Riedel , Erich Stoelben , Marcel Reiser , Holger Schulz , Stephan H. Schmitz , Konrad Frank , Reinhard Buettner , Juergen Wolf Journal of Clinical Oncology 2012 30, no. 18_suppl

CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study. Agnieszka Korfel , Gerald Illerhaus , Mathias Haenel , Robert Moehle , Roland Schroers , Thomas Elter , Marcel Reiser , Martin H. Dreyling , Jan Eucker , Christian Winfried Scholz , Bernd Metzner , Alexander Roeth , Josef Birkmann , Uwe S. Schlegel , Peter Martus , Eckhard Thiel , Lars Fischer Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8031-8031.

Non-interventional study of rituximab in the treatment of Chronic Lymphocytic Leukaemia (CLL NIS): first interim results Reiser, M. 1 , Hensel, M. 2 , Hoesl, M. 3 , Janssen, J. 4 , Jentsch- Ullrich, K. 5 , Koenigsmann, M. 6 , Lück, A. 7 , Schwarzer, A. 8 , Tschechne, B. 9 , Hechenbichler, K. 10 , Kellershohn, K. 11 , Maschmeyer, G. Onkologie 2012;35(suppl 6):1-259 P723

Romiplostim for the treatment of adults with primary Immune Thrombocytopenia (ITP) in routine clinical practice in Germany - Interim results from an observational study (PLATEAU) Welslau, M. 1 , Reiser, M. 2 , Illmer, T. 3 , Schlag, R. 4 , Josten, K. 5 , Dietzfelbinger, H. 6 , Tschechne, B. 7 , Schaffrik, M. 8 , Sölch, J.-P Onkologie 2012;35(suppl 6):1-259 P740

Management of secondary immunodeficiency (SID) under clinical practice conditions Hensel, M. 1 , Baumann, U. 2 , Gold, R. 3 , Borte, M. 4 , Fasshauer, M. 4 , Pittrow, D. 5 , Kirch, W. 5 , Huscher, D. 6 , Stangel, M. 7 , Reiser, M . 8 , for the SIGNS group Onkologie, Köln, Germany Onkologie 2012;35(suppl 6):1-259 P758

SORAVE: Phase I study for the treatment of relapsed solid tumours with the combination of sorafenib and everolimus Nogová, L. 1 , Mattonet, C. 1 , Scheffler, M. 1 , Bos, M. 1 , Gardizi, M. 1 , Papachristou, I. 1 , Rokitta, D. 2 , Fuhr, U. 2 , Kinzig, M. 3 , Sörgel, F. 3 , Kahraman, D. 4 , Kobe, C. 4 , Rhiem, K. 5 , Mallmann, P. 5 , Schnell, R. 6 , Katay, I. 7 , Schlaak, M. 8 , Dietlein, M. 4 , Wolf, J. Onkologie 2012;35(suppl 6):1-259 V681  Â

Results of the first interim analysis of the CARMA study to investigate efficacy and safety profile of catumaxomab in clinical practice. Volker Kunzmann , Jalid Sehouli , Barbara Schmalfeldt , Pauline Wimberger , Christian M. Kurbacher , G.-F. Tempelhoff , Udo J. Vanhoefer , P. Ebeling , F. Breuer , Holger Schulz , Manfred Welslau , Dominique Finas , Jaqueline Sagasser , M. Kiehl , S. Fruehauf Journal of Clinical Oncology 2012 30, no. 15_suppl